+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma



Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma



Neoplasma 63(2): 282-287



Thymidylate synthase (TS) plays an essential role in the pathogenesis and development of cancer, and TS-targeting agents have been widely used against different types of cancers. However, it remains still unclear whether or not TS is expressed in malignant melanoma. We conducted the clinicopathological study to investigate the prognostic significance of TS expression in cutaneous malignant melanoma. Ninety-nine patients with surgically resected cutaneous malignant melanoma were assessed. Tumor sections were stained by immunohistochemistry for TS, Ki-67, and microvessel density (MVD) determined by CD34. TS was positively expressed in 26% (26 out of 99). The expression of TS was significantly associated with T factor, cell proliferation (Ki-67) and MVD (CD34). By Spearman's rank test, TS expression was significantly correlated with Ki67 and CD34. By univariate analysis, ulceration, disease stage, TS, Ki-67 and CD34 had a significant relationship with survival. Multivariate analysis confirmed that TS was an independent prognostic factor for poor prognosis of cutaneous malignant melanoma. The positive expression of TS could be a useful marker for predicting poor prognosis in patients with cutaneous malignant melanoma, and TS-targeting agents may be worth trying for the treatment of this dismal disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637373

Download citation: RISBibTeXText

PMID: 26774151

DOI: 10.4149/215_150714N389


Related references

Expression of thymidylate synthase (TS) and its prognostic significance in patients with cutaneous angiosarcoma. Neoplasma 64(6): 916-921, 2017

Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. Biomarkers 19(1): 70-76, 2014

Expression and prognostic significance of Cathepsin L in early cutaneous malignant melanoma. Neoplasma 53(3): 259-262, 2006

Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. European Journal of Surgical Oncology 38(11): 1058-1064, 2013

Prognostic significance of thymidylate synthase expression in pancreatic adenocarcinoma: A meta-analysis. Molecular and Clinical Oncology 3(1): 121-124, 2014

Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy. Urology 69(5): 988-995, 2007

Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. Journal of Dermatological Science 64(1): 39-44, 2012

Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. Anticancer Research 31(9): 2763-2771, 2011

Tissue factor has no prognostic significance in primary cutaneous malignant melanoma. Melanoma Research 7(SUPPL 1): S132, 1997

Prognostic significance of LKB1 promoter methylation in cutaneous malignant melanoma. Oncology Letters 14(2): 2075-2080, 2017

Prognostic significance of cutaneous depigmentation in Mexican patients with malignant melanoma. Archives of Medical Research 29(2): 155-158, 1998

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunology, ImmunoTherapy 58(7): 1085-1094, 2008

Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiology, Biomarkers and Prevention 17(4): 949-958, 2008

The prognostic significance of basic fibroblastic growth factor in cutaneous malignant melanoma. Modern Pathology 7(1): 43A, 1994

The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma. Journal of Cutaneous Pathology 23(6): 506-510, 1996